Harmony Biosciences Holdings, Inc.

NasdaqGM:HRMY Stock Report

Market Cap: US$1.9b

Harmony Biosciences Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jeffrey Dayno

Chief executive officer

US$4.5m

Total compensation

CEO salary percentage13.8%
CEO tenure1.8yrs
CEO ownershipn/a
Management average tenure3.8yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points

Nov 11

Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Oct 31
Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?

Oct 30
Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?

Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Sep 25
Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Harmony Biosciences: Advancing An Expanded Pipeline

Aug 15

Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet

Jul 15
Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet

Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Jun 07
Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 03
Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely

Apr 04
These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely

Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Feb 09
Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Mar 21
Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?

Dec 01
Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?

Harmony Biosciences: In Harmony

Sep 23

We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease

Aug 05
We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease

Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M

Aug 02

Harmony Biosciences: Steady Revenue Generator Looking For A Future

May 26

CEO Compensation Analysis

How has Jeffrey Dayno's remuneration changed compared to Harmony Biosciences Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$123m

Jun 30 2024n/an/a

US$115m

Mar 31 2024n/an/a

US$138m

Dec 31 2023US$4mUS$613k

US$129m

Sep 30 2023n/an/a

US$151m

Jun 30 2023n/an/a

US$200m

Mar 31 2023n/an/a

US$189m

Dec 31 2022US$762kUS$459k

US$181m

Sep 30 2022n/an/a

US$156m

Jun 30 2022n/an/a

US$58m

Mar 31 2022n/an/a

US$49m

Dec 31 2021US$703kUS$446k

US$35m

Sep 30 2021n/an/a

US$12m

Jun 30 2021n/an/a

US$17m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$3mUS$431k

-US$64m

Sep 30 2020n/an/a

-US$110m

Jun 30 2020n/an/a

-US$146m

Mar 31 2020n/an/a

-US$165m

Dec 31 2019US$672kUS$414k

-US$187m

Compensation vs Market: Jeffrey's total compensation ($USD4.45M) is about average for companies of similar size in the US market ($USD5.34M).

Compensation vs Earnings: Jeffrey's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Jeffrey Dayno (67 yo)

1.8yrs

Tenure

US$4,450,294

Compensation

Dr. Jeffrey M. Dayno, M.D. serves as President, Chief Executive Officer and Director at Harmony Biosciences, LLC since 2023 and served as its Interim President and Chief Executive Officer since January 06,...


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Aronin
Founder & Non-Executive Chairman7.1yrsUS$185.67k0.44%
$ 8.4m
Jeffrey Dayno
President1.8yrsUS$4.45mno data
Sandip Kapadia
Executive VP3.7yrsUS$5.58m0.049%
$ 928.2k
Kumar Budur
Executive VP and Chief Medical & Scientific Officerless than a yearUS$760.81k0.0018%
$ 33.3k
Jeffrey Dierks
Executive VP & Chief Commercial Officer6.3yrsUS$5.60m0%
$ 0
Andrew Serafin
Executive VP & Chief Strategy Officer5.9yrsUS$647.43k0%
$ 0
David Bradshaw
Head of Technical Operationsno datano datano data
Brennan Doyle
VP & Head of Investor Relationsno datano datano data
Christian Ulrich
General Counsel & Corporate Secretary3.8yrsno datano data
Tricia Glover
Chief Compliance Officer3.5yrsno datano data
Audrey Murphy
Vice Presidet of Human Resourcesno datano datano data
Cate McCanless
Head of Corporate Affairs & Public Policyno datano datano data

3.8yrs

Average Tenure

54yo

Average Age

Experienced Management: HRMY's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Aronin
Founder & Non-Executive Chairman7.1yrsUS$185.67k0.44%
$ 8.4m
Jeffrey Dayno
President1.8yrsUS$4.45mno data
Andreas Wicki
Independent Director7.2yrsno datano data
R. Graf
Independent Director4yrsUS$179.99k0%
$ 0
Gary Sender
Independent Director4.3yrsUS$303.00k0%
$ 0
Antonio Gracias
Independent Director7.2yrsUS$235.00k0%
$ 0
Peter Anastasiou
Independent Directorless than a yearUS$132.51kno data
Linda Szyper
Independent Director3yrsUS$174.99k0%
$ 0
Juan Sabater
Independent Director7.8yrsUS$179.99k0%
$ 0

4.3yrs

Average Tenure

59yo

Average Age

Experienced Board: HRMY's board of directors are considered experienced (4.3 years average tenure).